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The accuracy and precision of the procedure and the values observed in normal individuals are similar to results ohmined by us previously (1) and by others (2, 3) .
Nonetheless,
the proposed methodology has several dinadvantages worth noting. The heating cycle is relatively long, which slows the rate at which samples can be run. Thus far, our efforts to significantly decrease the duration of the heating cycle have been unsuccessful. The need to use prediluted samples is another disadvantage. It would obviously be much more convenient to assay serum samples directly, but our attempts to use undiluted serum have not been successful, presumably because the matrix modifier does not mix easily with undiluted serum. Finally, we recognize that our method yields only a small absorbance value for serum containing physiological (<10 /1g/L) amounts of aluminum. In this instance we have found that scrupulous care must be taken to avoid contamination because contamination is the major limiting factor. In addition, we recommend the routine use of triplicate dilutions in this concentration range to improve the absolute precision of the assay. Recent data (6-B) suggest that cyclic GMP (cGMP) is the "second messenger" of ANF. Like ANF, it is increased in patients with various heart diseases (9) (10) (11) . A significant correlation of cGMP with right atrial pressure and other hemodynamic variables, as well as with clinically assessed severity of congestive heart failure (10), has been shown. Owing to its high in vitro stability and easy pre-analytical handling, cGMP may in the future become a routinely measured analyte in cardiology. As far as we know, no studies have focused on age-and blood pressure-dependent changes in cGMP.
Profound knowledge of the physiological states of a system and of its modifring factors is needed to define pathological conditions. With the determination of normal values, the sensitivity and specificity of various measurements can be assessed. They are useful tools for evaluating both the quality of the methods and the epidemiological implications of the results.
However, contradictory results have been reported concerning the influence of blood pressure on ANF concentrations in plasma. Some (12-16) have found increased ANF in patients with hypertension and describe a positive correlation of ANF with blood pressure; others (17, 18) could find no influence of blood pressure on ANF. Some investigators report an increase of ANF in the elderly (19) (20) (21) , but only a few patients were studied in most reports, and patients with heart diseases have not always been excluded (19) .
The aim of this study was therefore to investigate (b) dependence of ANF and cGMP on heart rate, age, and sex; (c) the influence of blood donation on ANF, cGMP, and other variables; and
of reference values for a representative number of healthy individuals for the analytical methods described below. Blood donors are a valuable group of healthy individuals who seem suitable as sources of normal values in a representative number of persons. We investigated ANF and cGMP in such subjects in relation to blood pressure, heart rate, age, sex, and factors of physical constitution.
Materials and Methods
For ANF and cGMP determination, plasma was separated by centrifugation immediately after blood withdrawal, frozen in liquid nitrogen, and stored at -20 #{176}C until assayed. The stability of ANF in plasma at room temperature is critical, but immediate processing yielded recovery rates of 97.9% (22) . No significant deterioration was observed on prolonged storage at -25 #{176}C (22) . ANF concentrations in plasma were measured by means of a commercially available 1251-labeled radioimmunoassay without prior extraction (from Eiken, Tokyo, Japan; purchased from Behring-Institut, Vienna, Austria). Samples were assayed in one run; the intra-assay coefficient of variation (CV) was 11.2%.
For cGMP determination we used a 3H-labeled radioimmunoassay (from Amersham International Ltd., Amersham, Bucks., U.K.) after extraction ofsamples with ether. cGMP in EDTA plasma was stable at room temperature and at 4 #{176}C for several days (unpublished observations). The intra-assay CV was 6.4%; the interassay CV was 13.6%. Protocol 1 .Ethi cal and technical considerations make it desirable to submit donors to only one venipuncture. For this reason, and to prevent contamination, sample collection in routine blood donation must take place at the end of the donation period. To correct the data for the influence of blood donation on ANF and cGMP, we followed an extended protocol in a small number of volunteers. Twentyseven such volunteers gave informed consent. Before blood donation they were carefully questioned by a specially trained physician for a history of hypertension, cardiac or thyroid disease, as well as medical therapy. Age, height, weight, and heart rate were recorded. Blood pressure was measured before and after blood donation. For the determination of ANF and cGMP, as well as standard erythrocyte measurements,
we obtained one sample before and one after the donation of 400 mL of blood. Blood specimens for erythrocyte count and mean corpuscular volume were analyzed with a standard cell counter (Coulter Electronics, Hialeah, FL). Hemoglobin was determined by the cyanhemoglobin method. The hematocrit value was calculated as erythrocyte count multiplied by mean corpuscular volume. The quotient ofhemoglobin and erythrocyte count gave the mean corpuscular hemoglobin. The mean corpuscular hemoglobin concentration was calculated as hemoglobin divided by erythrocyte count multiplied by mean corpuscular volume. In these cases we used special blood bottles that allowed separate blood withdrawal without contamination directly after venipuncture.
Protocol II. For determination of normal ANF and cGMP values, we investigated 139 healthy blood donors at two blood donation rallies of the Austrian Red Cross. Ten individuals who were receiving constant medication were excluded. Five more subjects had blood pressures exceeding 180/100 mmHg and were also excluded. The remaining 124 adult donors (72 men, 52 women) fulfilled international blood donation criteria. The interview covered the same questions as outlined above. Before blood donation, blood pressure and heart rate were measured with an automatic digital manometer (Dinamap, Criticon). The total body surface was calculated by the Du Bois formula: total body surface = 0.007184 x weight#{176}425 x height#{176}725. At the end of the donation period, 5 mL of blood was withdrawn into EDTA-containing tubes.
Statistical methods. For statistical analysis of paired data, we used the Wilcoxon matched-pairs signed-rank test. The 95%-confidence interval was calculated as the mean ± 1.96 times the standard deviation. For the determination of various influences (age, blood pressure, heart rate) on ANF and cGMP, a multivariance regression analysis was carried out (SPSS statistical software, 1986 ed.; Microsoft Corp., Cary, NC). Table 1 summarizes the main characteristics of the group investigated in Protocol 1. In the 27 volunteers, the mean time for blood donation, and thus mean 
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Range SD time between first and second sample withdrawals, was 380 s. During this 6.5-mm interval, there was a statistically significant decrease in hemoglobin and hematocrit values, and in erythrocyte count. Mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration remained unchanged.
We observed a significant decrease in diastolic blood pressure and mean arterial blood pressure. Even so, the decrease of systolic blood pressure was not yet statistically significant (P = 0.0506).
Interestingly, ANF concentrations in plasma increased from 78.9 (SEM 12.7) to 87.4 (SEM 11.1) ng/L ( Figure IA) . This change was statistically significant (P = 0.0035) and independent of age and basal ANF values. There was no correlation between the change of ANF and the duration of blood donation.
Blood donation had no significant influence on cGMP concentrations: 4.6 (SEM 0.6) nmol/L vs 4.5 (SEM 0.6) nmol/L ( Figure 1B) .
Protocol II. (Figure 2A ). When corrected for the influence of blood donation, the 95% confidence interval for ANF was 10.0 to 112.1 (mean 61.5) ngfL.
The mean cGMP concentration was 2.90 (SD 1.45) nmolJL, 95% confidence interval 0.04 to 5.75 nmollL ( Figure 2R ).
Multiple-regression analysis revealed no significant influence of age, heart rate, or blood pressure on the concentration of either ANF or cGMP in plasma.
Values for ANF and cGMP were also independent of body weight, height, and total body surface. Nor could we find any statistically significant correlation between ANF and cGMP concentration in plasma taken from these 124 healthy volunteers at rest.
The males and females in this group differed in respect to height, weight, blood pressure, and heart rate. The men were taller and heavier and had a significantly higher blood pressure than women: mean arterial pressure for men was 103.7, SD 11.06, vs 98.5, SD 10.28, mmHg for women. The women had a statistically significant higher heart rate: 84.4, SD 13.24, vs 76.0, SD 14.10, beats per minute.
Comparing ANF and cGMP concentrations of 72 male a Wilcoxon matched-pairssigned-ranktest. Hct = hematocrit,Hb = hemoglobin, EC = erythrocytecount, MCV = mean corpuscular volume, MCH = meancopuscuar hemoglobin, MCHC = mean corpuscularhemoglobin concentration, RRd = diastolic blood pressure, RRs = systolic blood pressure, MAP = mean arterialpressure,n.s., not significant (P >0.05). and 52 female volunteers, we could observe no significant differences.
Values for ANF were 68.5 (SD 23.62) ng/L in men and 70.8 (SD 29.26) ng/L in women; cGMP concentrations were 2.96 (SD 1.48) and 2.83 (SD 1.43) nmoIJL, respectively.
Discussion
The reason for the increase in ANF within 6.5 miii of blood donation is unclear. The work of Sonnenberg and Veress (23) led to the speculation that catecholamines may mediate ANF release. However, recent data show that a high concentration of circulating catecholamines does not increase ANF concentrations in plasma of healthy people (24) .
In the same individuals a significant drop in blood pressure had no influence on ANF concentrations. The stimulation ofthe autonomic (sympathetic) nervous system in hypertensive patients even induced a reduction of ANF values (25) . Therefore it seems unlikely that either increased catecholamine concentrations in plasma, or a slightly reduced cardiac output followed by decreased renal blood flow, could increase circulating concentrations of ANF.
According to our present knowledge, cGMP follows increasing ANF concentrations in plasma almost immediately. A study of volume loading as a stimulus to increased plasma ANF concentrations showed that a cGMP maximum occurs approximately 10 mm after the ANF peak (26) . Thus, the time of 6.5 mm between sample collection may be too short to detect a cGMP increase in response to increased plasma ANF. However, the exact delay between ANF release and a consequent increase in the circulating concentration of cGMP in plasma remains to be determined.
In accordance with reports from other authors (18, 19, 27) , we found no correlation between ANF concentrations and blood pressure in 124 normotensive healthy individuals. This again confirms that, within a normal range, blood pressure per se does not determine ANF release. These findings do not contradict data from other workers who have found increased ANF concentrations in plasma from patients with hypertension (12) (13) (14) (15) (16) . Long-lasting hypertension leads to left ventricular hypertrophy and, concomitantly, to a decreased left ventricular compliance, followed by increased atrial pressure. Apparently, these morphological changes in the heart, rather than increased blood pressure alone, cause increased circulating concentrations of ANF (13, 28) .
Several authors (19) (20) (21) have found increased ANF values in the elderly by comparing young and old healthy individuals. However, this approach is not appropriate for investigating the influence of age on biochemical variables. Multimorbidity increases with age-a factor that such methods are not able to eliminate.
Other authors report a significant positive correlation of ANF with age, sometimes only in normotensive subjects (13, 16) . In our group of 124 healthy normotensive subjects, the number of individuals in four different age groups was similar. We found no influence of age on ANF concentration. Again, it is not age per se that determines ANF concentrations in plasma, but rather age-related morphological changes, e.g., in the heart.
Although the 72 male and 52 female subjects differed in respect to weight, height, total body surface, blood pressure, and heart rate, plasma ANF concentrations were similar in both groups. This internal consistency again confirms that these factors have no influence on plasma ANF concentration. To our knowledge, the influence of age, blood pressure, heart rate, and sex on cGMP, the second messenger of ANF, has not yet been investigated.
As with ANF, we found no correlation between cGMP in plasma and blood pressure, age, or heart rate. cGMP values did not differ significantly between males and females.
A tight correlation ofANF with cGMP has been found in patients with various heart diseases (9-11). However, we found no such correlation in a group of 124 healthy subjects at rest.
ANF concentrations in plasma vary considerably during the day, but do not show an actual detectable diurnal rhythm (19) . We found similar results for cGMP in patients with mitral valve prolapse and healthy controls (Wencker et al., manuscript in preparation). Thus, at least three factors render the detection of a correlation between ANF and cGMP in vivo difficult: (a) the high intra-individual variations of both ANF and cGMP, (b) the delay between ANF release and cGMP increase, and (c) the different half-life of these biochemical variables in plasma. We conclude that, within the normal range of ANF and cGMP, seemingly stochastic fluctuations oftheir concentrations in plasma occur and mask the correlation. When ANF concentrations in plasma are increased in patients because of congestive heart failure or by physical exertion, and a broader range of values is taken into account, a correlation can again be observed.
This should be kept in mind when a comparison of samples collected on different days from subjects at rest is intended. Because of the considerable individual variations, one should always use the mean of several consecutive measurements to increase the comparability of values from one patient.
